Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas

@article{Holdhoff2012UseOP,
  title={Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas},
  author={Matthias Holdhoff and Xiaobu Ye and Jaishri O Blakeley and Lindsay Blair and Peter C. Burger and Stuart A. Grossman and Luis A Diaz},
  journal={Journal of Neuro-Oncology},
  year={2012},
  volume={110},
  pages={279-285}
}
This study was conducted to assess the current pattern of use and the impact of available molecular predictive and prognostic biomarkers on clinical care in patients with glioblastoma (GBM). An online questionnaire consisting of 15 questions about the frequency of use and clinical utility of tissue-based molecular tests was distributed to 1,053 members of the Neuro-Oncology Community in the United States. A total of 320 responses (30.4 %) were collected. 73 respondents who did not see GBM… CONTINUE READING

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

Glioblastoma – A tale of two tumors: Case comparison and literature review

  • Surgical neurology international
  • 2014
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 13 REFERENCES

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2006
VIEW 1 EXCERPT

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
VIEW 1 EXCERPT